US
USGOW
U.S. GoldMining Inc.
No data for this timeframe.
Vol
Market Cap$109.6M
Cap SizeMicro Cap
Inst. Holders1 funds
Inst. Value$563.00
Inst. Activity0 buys / 1 sells
SEC Reports2
Recent Activity
May 22, 2026
SEC
Nasdaq filed a Form 25-NSE to delist and deregister U.S. GoldMining Inc.'s warrants (exercisable at $13.00 per share) un
25-NSE — Impact 8/10
Apr 23, 2026
SEC
U.S. GoldMining Inc. extended the expiration date of its public warrants (USGOW) from April 24, 2026, to May 1, 2026, by
8-K — Impact 3/10
Inst.
UBS Group AG — TRIM
335 shares ($563.00)
Inst.
UBS Group AG — DOUBLED
646 shares ($588.00)
Apr 29, 2026
Event
Duavee
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE s
Latest Reports
BEARISH
25-NSE
8/10
Nasdaq filed a Form 25-NSE to delist and deregister U.S. GoldMining Inc.'s warrants (exercisable at $13.00 per share) un
May 22, 2026
NEUTRAL
8-K
3/10
U.S. GoldMining Inc. extended the expiration date of its public warrants (USGOW) from April 24, 2026, to May 1, 2026, by
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $563.00 | TRIM |
1 institutional holders with $563.00 total value (335 shares) as of 2025-Q3. Top holders: UBS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 335 | $563.00 | 100.0% | TRIM -48.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 646 | 335 | -48.1% | $563.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 252 | 646 | +156.3% | $588.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 15,116 | — | $19.8K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 2,619 | 252 | -90.4% | $302.00 | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 29, 2026
FDA
Duavee
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings